Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Notes Payables: 2020-2022

Historic Notes Payables for RedHill Biopharma (RDHL) over the last 3 years, with Dec 2022 value amounting to $115.2 million.

  • RedHill Biopharma's Notes Payables rose 37.79% to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year increase of 37.79%. This contributed to the annual value of $115.2 million for FY2022, which is 37.79% up from last year.
  • As of Q4 2022, RedHill Biopharma's Notes Payables stood at $115.2 million, which was up 1.19% from $113.9 million recorded in Q3 2022.
  • In the past 5 years, RedHill Biopharma's Notes Payables ranged from a high of $115.2 million in Q4 2022 and a low of $78.2 million during Q1 2020.
  • Its 3-year average for Notes Payables is $87.7 million, with a median of $83.3 million in 2021.
  • Data for RedHill Biopharma's Notes Payables shows a peak YoY skyrocketed of 37.79% (in 2022) over the last 5 years.
  • Over the past 3 years, RedHill Biopharma's Notes Payables (Quarterly) stood at $81.4 million in 2020, then rose by 2.74% to $83.6 million in 2021, then skyrocketed by 37.79% to $115.2 million in 2022.
  • Its Notes Payables was $115.2 million in Q4 2022, compared to $113.9 million in Q3 2022 and $85.5 million in Q2 2022.